What Vielight does

Vielight Inc. is a Toronto-based neurotechnology company founded in 2012 by Dr. Lew Lim that develops and sells at-home photobiomodulation (PBM) devices targeting brain and systemic health. Its core technology is a patented intranasal-transcranial PBM (itPBM) architecture using 810nm near-infrared Vie-LED modules that combine transcranial delivery (via concave-lens modules that bypass hair and scalp) with intranasal delivery through the cribriform plate to reach deep brain structures including the hippocampus, hypothalamus, and brainstem. The product portfolio spans the Neuro 4 series (Gamma 4 at $1,799, Alpha 4, Duo 4 at $2,399, and Pro 2 at $5,000 with 400 mW/cm² irradiance), the MIP multi-wavelength systemic device ($499), the X-Plus 4 for thymus stimulation ($449), and the Vagus NIR vagus nerve stimulator ($699), with devices certified to ISO 13485, MDSAP, and TÜV Rheinland standards.

Vielight sells primarily direct-to-consumer through its e-commerce platform (vielight.com) with global shipping, augmented by a 500+ practitioner channel, elite sports partnerships (BYU football, Haas Factory Team/NASCAR, UFC champion Ilia Topuria), and a government channel via the VA and Lovell Government Services for US veterans. The company also operates VIECLINIC, a Toronto psychiatric and neurological clinic combining EEG, rTMS, tDCS, and tPBM, and is preparing the soft launch of the Vielight-AI platform for EEG analysis in early 2026. Revenue is generated through one-time hardware sales with optional AI platform access bundled in (6-12 months depending on device tier), HSA/FSA eligibility, and reseller/affiliate commissions.

The company has positioned itself as the evidence leader in home-use brain PBM, claiming 30+ peer-reviewed studies with independent top-tier institutions including UCSF, Harvard Medical School, University of Toronto, University of Utah, Baycrest, and CAMH, with 100,000+ devices sold worldwide. A 228-participant pivotal Alzheimer's trial is underway with FDA and Health Canada protocol review, and a $4.6 million US Department of War grant is funding a 300-participant TBI trial at University of Utah and NYU. The company has raised a $3.5 million seed round from MaRS Discovery District and remains founder-controlled under Dr. Lew Lim.

Name

Vielight

Legal name

Vielight Inc.

Website

http://vielight.com/

Company type

Private

Founded year

2011

Operating status

Operating

Headcount range

11–50 employees

Short description

Vielight, based in Toronto, Canada is increasingly recognized to be the company that offers some of the most user-friendly

Ownership category

akta.pro rank

Product category

Consumer Neurotechnology

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Optoelectronic Emitters (LED/Laser/VCSEL) (HDAHALAL)

Keywords

• Brain photobiomodulation devices
• Near-infrared neurotechnology
• Intranasal light therapy
• Transcranial PBM systems
• Cognitive wellness hardware

Headquarters

HQ city

Toronto

HQ country

Canada

HQ region

North America

Offices2 records

Markets served

GTM type

B2C

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Operations

Revenue model

1. Hardware device sales: Vielight generates revenue primarily through direct sales of neurotechnology devices (brain PBM headsets and intranasal modules) priced from $449 to $5,000. Devices include Neuro Gamma 4 ($1,799), Neuro Duo 4 ($2,399), Neuro Pro 2 ($5,000), Neuro Alpha 4, MIP, X-Plus, and Vagus. One-time hardware purchase model with optional AI platform access.
2. VIECLINIC professional services: Vielight operates VIECLINIC, a psychiatric and neurological clinic in Toronto combining EEG, rTMS, tDCS, and tPBM technologies, generating professional services revenue.
3. Practitioner/reseller programs: Practitioners program enables clinicians to incorporate Vielight brain PBM technology into their practice with dedicated client support channels. Reseller and affiliate programs offer commissions and reseller discounts, creating channel-based revenue.

Pricing tiers

Go-to-market motion1 record

Distribution channels4 records

Marketing channels8 records

Core offering

Vielight designs, manufactures, and sells at-home brain photobiomodulation (PBM) devices that deliver 810nm near-infrared light through a patented intranasal-transcranial (itPBM) architecture to reach deep brain structures. Its Neuro product line (Gamma, Alpha, Duo, Pro 2) targets cognition, memory, focus, and recovery, complemented by systemic devices (MIP, X-Plus, Vagus) and an EEG-analysis AI platform. The company also operates VIECLINIC, a Toronto psychiatric and neurological clinic.

Product overview

Vielight is a neurotechnology company offering a portfolio of at-home brain and systemic photobiomodulation (PBM) devices. The core product line includes the Neuro series (Neuro Gamma 4, Neuro Alpha 4, Neuro Duo 4, and Neuro Pro 2) which deliver 810nm near-infrared light via transcranial and intranasal (itPBM) routes to target brain networks. Supporting devices include the MIP for systemic immunity, X-Plus for thymus/nasal stimulation, and Vagus for vagus nerve stimulation. The ecosystem is complemented by the Vielight-AI platform (AI/ML-powered EEG analysis) and VIECLINIC (clinical services). All brain devices use proprietary Vie-LED technology with industry-leading irradiance and are backed by 30+ published peer-reviewed studies.

Differentiator

Problem solved

Functional benefit

Brands

• Vieclinic: Psychiatric and neurological clinic combining EEG, rTMS, tDCS, and tPBM technologies
• Vielight Sports
• Vielight-AI
• Vie-LED

Products and services

• Vielight Neuro Gamma 4 Transcranial-intranasal PBM helmet delivering 810nm near-infrared light at 40Hz Gamma frequency via five Vie-LED modules and a patented intranasal applicator, designed to enhance cognition, memory, and brain resilience.
• Vielight Neuro Alpha 4 Brain PBM device that pulses near-infrared light at 10Hz Alpha frequency through combined transcranial and intranasal delivery to support relaxation, mindfulness, learning, and recovery.
• Vielight Neuro Duo 4 Dual-frequency brain PBM device that combines Alpha (10Hz) and Gamma (40Hz) pulsed modes, allowing users to switch between relaxed and focused mental states.
• Vielight Neuro Pro 2 Most powerful and customizable Vielight brain PBM device featuring 9 preset protocols via the Neuro Pro App, 400 mW/cm² irradiance, and a pre-synced smartphone for guided brain photobiomodulation sessions.
• Vielight MIP 470-633-655-810 Multi-wavelength systemic/intranasal PBM device combining 470, 633, 655, and 810nm light to support immunity, oxygenation, gentle brain stimulation, and intranasal microbial sanitization.
• Vielight X-Plus 4 Device that stimulates the thymus gland and nasal vasculature with light energy to improve immunity and systemic fitness.
• Vielight Vagus Non-invasive near-infrared vagus nerve stimulator that uses photobiomodulation to enhance brain-body connectivity, mental clarity, stress reduction, and physical and mental wellbeing.
• Vielight-AI Platform AI and machine learning platform that analyzes EEG data files to help researchers, clinicians, and home users assess how their brain responds to brain photobiomodulation.
• VIECLINIC Toronto-based psychiatric and neurological clinic operated by Vielight that combines EEG, rTMS, tDCS, and transcranial PBM technologies for comprehensive neurotechnology-based brain interventions.

Quantifiable outcome

• Episodic recognition memory improved by large effect size (d=1.09, p=0.02) in MCI patients using Vielight Neuro itPBM for 6 weeks vs. sham
• +7 more outcomes

Named customers6 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration5 records

AI capability4 records

Feature5 records

Partnerships

Ten partnerships are on record, tiered core and minor.

• Haas Factory Team (NASCAR)coreStrategic or Co-development Partner · 18 June 2026Vielight partnered with Haas Factory Team (NASCAR) in June 2026 to bring brain health into the sports conversation. The partnership aims to raise awareness of neurotechnology for athletes, emphasizing brain health considerations from high-speed racing to contact sports. Represents Vielight's expansion into motorsports for visibility and sports performance validation.
• University of TorontocoreStrategic or Co-development PartnerMultiple research collaborations with University of Toronto including the MCI pilot trial (n=20, published in Journal of Alzheimer's Disease June 2026), ongoing n=60 MCI clinical trial, viral recovery study, and EEG neuromodulation study. Key researchers include Dr. Neda Rashidi-Ranjbar (MD, PhD) and Dr. Corinne Fischer (MD, PhD).
• St. Michael's Hospital (Toronto)coreStrategic or Co-development PartnerClinical trial site for Vielight's MCI research and pivotal Alzheimer's trial (n=228). St. Michael's Hospital is a major teaching hospital affiliated with the University of Toronto. Dr. Corinne Fischer serves as principal investigator. The hospital's Applied Health Research Centre (AHRC) independently manages the pivotal Alzheimer's trial.
• University of UtahcoreStrategic or Co-development PartnerMulti-phase TBI research collaboration with University of Utah's Traumatic Brain Injury and Concussion Center. Phase 1 (n=49) and Phase 2 (n=44) published studies showing cognitive and motor improvements. Currently leading the landmark $4.6M DoD-funded 300-participant clinical trial. Key researchers: Dr. Elisabeth Wilde and Dr. Carrie Esopenko. Published in Journal of Neurotrauma (2026).
• Baycrest HospitalcoreStrategic or Co-development PartnerPublished study (n=45) investigating Vielight's itPBM technology's effect on the brain's glymphatic system (waste clearance network). Key finding: intranasal channel is 20x more efficient than transcranial-only at improving brain fluid dynamics. Study highlights the efficiency advantage of Vielight's dual-pathway approach.
• Brigham Young University (BYU)coreStrategic or Co-development PartnerBYU football team adopted Vielight Neuro Duo as standard equipment for the 2024 season (11-2 record, No. 13 AP ranking). Tom Holmoe, 3x Super Bowl Champion and BYU Associate Athletic Director, cited compelling photobiomodulation research from University of Utah. Performance research team led by Dr. Coleby Cloawson. Two NFL teams reportedly evaluating the technology.
• Lovell Government Service / VAcoreChannel Partner/ Reseller/ DistributorPartnership to serve US veterans and service members with Vielight neurotechnology through the VA (Veterans Affairs) system. Provides access to Vielight devices for veterans, particularly those with mTBI and cognitive concerns.
• Centre for Addiction and Mental Health (CAMH)coreStrategic or Co-development PartnerCAMH researcher Reza Zomorrodi served as lead investigator on the 2019 Nature Scientific Reports EEG neuromodulation study showing Vielight Neuro Gamma modulates brain oscillations within 20 minutes. First demonstration that home-use PBM device produces significant neuromodulation.
• University of CalgaryminorStrategic or Co-development PartnerUniversity of Calgary's biophysics lab conducted a cellular study testing Vielight Neuro Pro 2's NIR light on cancer cells, finding differential effects on normal vs. cancer cell metabolism — PBM enhanced viability in normal cells while potentially reducing cancer cell viability under defined conditions. Co-authors include Jack Tuszynsky's team at University of Alberta.
• UCSFcoreStrategic or Co-development PartnerUCSF fMRI study reveals Vielight Neuro Gamma's 40Hz itPBM improves ADAS-cog scores by 4.8 points, increasing cerebral perfusion and DMN connectivity in Alzheimer's patients. UCSF research validates Vielight's technology for cognitive decline intervention.

Scale indicators10 records

Recent moves7 records

Expansion highlights8 records

Direct peers

• Cognito Therapeutics: Cognito Therapeutics develops light- and sound-based gamma-frequency stimulation devices (Spectris) for Alzheimer's and other neurodegenerative diseases. It is the closest direct competitor to Vielight's Neuro Gamma 40Hz itPBM platform in mechanism and target indication.
• Neuronetics: Neuronetics manufactures transcranial magnetic stimulation (TMS) systems (NeuroStar) for major depressive disorder, an FDA-cleared non-invasive brain stimulation therapy. It is directly comparable to Vielight as a non-invasive neurostimulation device company targeting CNS indications.
• Brainsway: Brainsway markets deep TMS systems (Deep TMS) with FDA-cleared indications in depression, OCD, and smoking cessation. It competes with Vielight in the non-invasive brain stimulation device category targeting psychiatric and neurological disorders.
• electroCore: electroCore makes gammaCore, a non-invasive vagus nerve stimulation (nVNS) device FDA-cleared for migraine, cluster headache, and stroke rehabilitation. It directly overlaps with Vielight's Vagus product line and broader non-invasive neuromodulation positioning.
• Muse (Interaxon): Muse sells consumer EEG-mediated neurofeedback headbands marketed for sleep, focus, and meditation. It targets the same at-home brain wellness consumer as Vielight Neuro and is integrated with the Vielight-AI EEG analysis platform.
• Emotiv: Emotiv produces consumer and research-grade EEG headsets (EPOC, Insight) used for brain-computer interface, research, and wellness applications. Like Muse, Emotiv is both a Vielight-AI integration partner and a competitor in the consumer neurotech/wellness category.

Emerging players

• MindMaze: MindMaze builds digital neurotherapeutic platforms (MindPod, MindMotion) for stroke rehabilitation and cognitive recovery. It overlaps with Vielight's clinical TBI/stroke-rehabilitation positioning through a software-led, rather than light-based, modality.
• Kernel: Kernel develops non-invasive brain sensing wearables (Flow, Flux) measuring brain activity for cognitive performance and clinical research. It overlaps with Vielight in the premium consumer neurotech category and shares the broader aim of bringing brain metrics out of the clinic.
• Hapbee Technologies: Hapbee sells a wearable that delivers low-power electromagnetic signals for mood, sleep, and wellness effects without drugs. It is a directly adjacent consumer wearable targeting the same wellness/performance buyer as Vielight, though via a different physical modality.

Broad incumbents

• Posit Science (BrainHQ): Posit Science commercializes BrainHQ, a computerized cognitive training platform with clinical evidence in cognitive aging and dementia risk reduction. It is a broad-incumbent peer competing for the same MCI / cognitive-decline customer as Vielight.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• YouTubeyoutube.com/@VielightInc
• Xx.com/vielightinc
• Facebookfacebook.com/vielight

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Vielight